表紙
市場調査レポート

肝硬変 : パイプライン分析

Liver Cirrhosis - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 213038
出版日 ページ情報 英文 102 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
肝硬変 : パイプライン分析 Liver Cirrhosis - Pipeline Review, H1 2016
出版日: 2016年03月30日 ページ情報: 英文 102 Pages
概要

肝硬変とは、各種の肝臓病・疾患(肝炎・慢性アルコール中毒など)が原因で発症する、肝臓の瘢痕状態のことを指します。瘢痕組織により肝臓の正常構造が損傷され、更には肝臓内の血流にも悪影響が及ぼします。主な症状として、食欲不振や皮膚の痒み、体重減少、疲労感、吐き気などが挙げられます。主な治療法には肝移植手術などがあります。

当レポートでは、世界各国での肝硬変治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査して、その結果をお届けします。

目次

イントロダクション

  • 分析範囲

肝硬変の概要

治療薬の開発

  • 肝硬変向けパイプライン製品:概要
  • 肝硬変向けパイプライン製品:比較分析

各企業で開発中の肝硬変治療薬

大学/研究機関で研究中の肝硬変治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

肝硬変治療薬:開発中の製品の一覧(企業別)

肝硬変治療薬:研究中の製品の一覧(大学/研究機関別)

肝硬変治療薬の開発に従事している企業

  • Alfa Wassermann S.p.A
  • Conatus Pharmaceuticals Inc.
  • Digna Biotech, S.L.
  • Galectin Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • GNI Group Ltd.
  • Human Stem Cells Institute
  • Nimbus Therapeutics, LLC
  • PharmaIN Corporation
  • Pharmicell Co., Ltd.
  • S-Evans Biosciences, Inc.
  • Stelic Institute & Co.
  • Stempeutics Research Private Limited

肝硬変:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • (sofosbuvir + velpatasvir)
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • 肝硬変向け細胞療法
  • DB-027
  • DB-036
  • emricasan
  • F-351
  • Gemacell
  • GR-MD-01
  • GR-MD-02
  • GXHPC-1
  • Livercellgram
  • HCV関連肝硬変用TGF-β?型受容体のモノクローナル抗体
  • ND-654
  • Px-104
  • リファキシミン
  • simtuzumab
  • 肝硬変向け幹細胞療法
  • 肝硬変向け幹細胞療法
  • 肝線維症および肝硬変向け幹細胞療法S
  • 代謝・胃腸・呼吸器系障害向け幹細胞療法
  • 関節リウマチ・肝硬変向け幹細胞療法
  • Stempeucel
  • STNM-04
  • thrombopoietin
  • 肝硬変向けの未公開ペプチド

肝硬変治療薬:パイプライン製品の最新動向

肝硬変治療薬:開発が休止状態の製品

肝硬変治療薬:開発が中止された製品

肝硬変関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7728IDB

Summary

Global Markets Direct's, 'Liver Cirrhosis - Pipeline Review, H1 2016', provides an overview of the Liver Cirrhosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Liver Cirrhosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Cirrhosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Liver Cirrhosis
  • The report reviews pipeline therapeutics for Liver Cirrhosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Liver Cirrhosis therapeutics and enlists all their major and minor projects
  • The report assesses Liver Cirrhosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Liver Cirrhosis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Liver Cirrhosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Liver Cirrhosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Liver Cirrhosis Overview
  • Therapeutics Development
    • Pipeline Products for Liver Cirrhosis - Overview
    • Pipeline Products for Liver Cirrhosis - Comparative Analysis
  • Liver Cirrhosis - Therapeutics under Development by Companies
  • Liver Cirrhosis - Therapeutics under Investigation by Universities/Institutes
  • Liver Cirrhosis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Liver Cirrhosis - Products under Development by Companies
  • Liver Cirrhosis - Products under Investigation by Universities/Institutes
  • Liver Cirrhosis - Companies Involved in Therapeutics Development
    • Conatus Pharmaceuticals Inc.
    • Digna Biotech, S.L.
    • Galectin Therapeutics, Inc.
    • Gilead Sciences, Inc.
    • GNI Group Ltd.
    • Human Stem Cells Institute
    • INVENT Pharmaceuticals, Inc.
    • Nimbus Therapeutics, LLC
    • Pacific Therapeutics Ltd.
    • PharmaIN Corporation
    • Pharmicell Co., Ltd.
    • S-Evans Biosciences, Inc.
    • Stelic Institute & Co., Inc.
    • Stempeutics Research Private Limited
  • Liver Cirrhosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (sofosbuvir + velpatasvir) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DB-027 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DB-036 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • emricasan - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • F-351 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gemacell - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GRMD-02 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GXHPC-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INV-340 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Livercellgram - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies to Antagonize TGF-Beta Receptor Type-1 for HCV associated Liver Cirrhosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ND-654 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PTL-303 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Liver Cirrhosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Metabolic, Gastrointestinal and Respiratory Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Rheumatoid Arthritis and Liver Cirrhosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stempeucel - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • STNM-04 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide for Liver Cirrhosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • thrombopoietin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Liver Cirrhosis - Recent Pipeline Updates
  • Liver Cirrhosis - Dormant Projects
  • Liver Cirrhosis - Discontinued Products
  • Liver Cirrhosis - Product Development Milestones
    • Featured News & Press Releases
      • Jan 05, 2016: Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial
      • Nov 16, 2015: Conatus Pharmaceuticals Announces Late-Breaking Oral Presentation at AASLD Annual Meeting
      • Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting
      • Oct 20, 2015: Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting
      • Oct 01, 2015: Conatus Pharmaceuticals Announces Acceptance of Abstracts for AASLD Annual Meeting
      • Jun 25, 2015: Conatus Announces Initial Baseline Data From Phase 2b POLT-HCV-SVR Clinical Trial of Emricasan Confirming Activity of Relevant Mechanisms and Opportunity for Histological Improvement
      • May 14, 2015: Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam
      • Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting
      • Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting
      • Sep 02, 2014: Conatus Pharmaceuticals Initiates Phase 2 Trial in Patients with Liver Cirrhosis and Separate Open Label Phase 2 Trial in Cirrhosis Patients with Portal Hypertension
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Liver Cirrhosis, H1 2016
  • Number of Products under Development for Liver Cirrhosis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Liver Cirrhosis - Pipeline by Conatus Pharmaceuticals Inc., H1 2016
  • Liver Cirrhosis - Pipeline by Digna Biotech, S.L., H1 2016
  • Liver Cirrhosis - Pipeline by Galectin Therapeutics, Inc., H1 2016
  • Liver Cirrhosis - Pipeline by Gilead Sciences, Inc., H1 2016
  • Liver Cirrhosis - Pipeline by GNI Group Ltd., H1 2016
  • Liver Cirrhosis - Pipeline by Human Stem Cells Institute, H1 2016
  • Liver Cirrhosis - Pipeline by INVENT Pharmaceuticals, Inc., H1 2016
  • Liver Cirrhosis - Pipeline by Nimbus Therapeutics, LLC, H1 2016
  • Liver Cirrhosis - Pipeline by Pacific Therapeutics Ltd., H1 2016
  • Liver Cirrhosis - Pipeline by PharmaIN Corporation, H1 2016
  • Liver Cirrhosis - Pipeline by Pharmicell Co., Ltd., H1 2016
  • Liver Cirrhosis - Pipeline by S-Evans Biosciences, Inc., H1 2016
  • Liver Cirrhosis - Pipeline by Stelic Institute & Co., Inc., H1 2016
  • Liver Cirrhosis - Pipeline by Stempeutics Research Private Limited, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Liver Cirrhosis Therapeutics - Recent Pipeline Updates, H1 2016
  • Liver Cirrhosis - Dormant Projects, H1 2016
  • Liver Cirrhosis - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Liver Cirrhosis, H1 2016
  • Number of Products under Development for Liver Cirrhosis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top